Literature DB >> 10608816

Vitronectin interaction with glycosaminoglycans. Kinetics, structural determinants, and role in binding to endothelial cells.

P P François1, K T Preissner, M Herrmann, R P Haugland, P Vaudaux, D P Lew, K H Krause.   

Abstract

Vitronectin (VN) is a high affinity heparin-binding protein. The physiological role of this binding has hitherto received little attention, and its molecular determinants are subject to controversy. In this study, we characterized vitronectin interaction with heparin, heparin analogues, bacterial extracts, and cell surface glycosaminoglycans. As assessed by (i) fluorescence assays, (ii) precipitation with heparin-Sepharose beads, or (iii) Western blotting with antibodies against VN(347-361) (the heparin-binding site), we demonstrate an exposure of the VN heparin-binding site in multimeric but not monomeric vitronectin. Through its heparin-binding site, vitronectin also bound other glycosaminoglycans and Staphylococcus aureus extracts. The kinetics of heparin binding to vitronectin were complex. After a fast association phase (tau = 0.3 s), a slow conversion of an unstable to a stable heparin-vitronectin complex (tau = 180 s) occurred. Heparin binding kinetics and transition to a stable complex were mimicked by VN(347-361), demonstrating that this area is the fully functional heparin-binding site of vitronectin. Multimeric vitronectin bound to endothelial cells. This binding was blocked by soluble heparin and was not observed when endothelial cells were pretreated with glycosaminoglycan-removing enzymes. Glycosaminoglycan-dependent interaction of endothelial cells with multimeric vitronectin might be a relevant mechanism for removal of multimeric vitronectin from plasma. Conversion of an unstable to a stable glycosaminoglycan-vitronectin complex is likely to be relevant for association with endothelial cells under flow conditions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10608816     DOI: 10.1074/jbc.274.53.37611

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Identification and characterization of a novel 38.5-kilodalton cell surface protein of Staphylococcus aureus with extended-spectrum binding activity for extracellular matrix and plasma proteins.

Authors:  M Hussain; K Becker; C von Eiff; J Schrenzel; G Peters; M Herrmann
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

2.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

3.  Heterologously expressed Staphylococcus aureus fibronectin-binding proteins are sufficient for invasion of host cells.

Authors:  B Sinha; P Francois; Y A Que; M Hussain; C Heilmann; P Moreillon; D Lew; K H Krause; G Peters; M Herrmann
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

4.  New insights into heparin binding to vitronectin: studies with monoclonal antibodies.

Authors:  P Anne Underwood; Alan Kirkpatrick; Sue M Mitchell
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

5.  Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner.

Authors:  S Edwards; P F Lalor; C Tuncer; D H Adams
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

6.  Altered Protein Function Caused by AMD-associated Variant rs704 Links Vitronectin to Disease Pathology.

Authors:  Fabiola Biasella; Karolina Plössl; Claudia Karl; Bernhard H F Weber; Ulrike Friedrich
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

7.  Candida albicans uses the surface protein Gpm1 to attach to human endothelial cells and to keratinocytes via the adhesive protein vitronectin.

Authors:  Crisanto M Lopez; Reinhard Wallich; Kristian Riesbeck; Christine Skerka; Peter F Zipfel
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

8.  Vitronectin expression in the airways of subjects with asthma and chronic obstructive pulmonary disease.

Authors:  Lina M Salazar-Peláez; Thomas Abraham; Ana M Herrera; Mario A Correa; Jorge E Ortega; Peter D Paré; Chun Y Seow
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.